Case Studies in Thyroid Cancer

Key opinion leaders review clinical cases in thyroid cancer, focusing on recent advances, treatment options, and clinical trials impacting clinical practice.

EP. 1: Case 1: RAI-Refractory DTC

September 28th 2021

Andrew Gianoukakis, MD, reviews the case of a 71-year-old woman with RAI-refractory differentiated thyroid cancer and the panel discuss relevant clinical trial data.

EP. 2: Case 1: Considerations of RAI Use

September 28th 2021

Experts in thyroid cancer discuss treatment considerations surrounding the use of radioiodine therapy in patients with thyroid cancer.

EP. 3: Case 1: Treatment Considerations for Refractory DTC

September 28th 2021

Andrew Gianoukakis, MD, reviews the treatment and management options for a 71-year-old woman with RAI- refractory differentiated thyroid cancer.

EP. 4: RR-DTC: Definition and Clinical Presentation

September 28th 2021

The panel of experts share their insights into the definition and clinical presentation of radioiodine-refractory DTC.

EP. 5: RAI Treatment: Impact of Mutation Status

September 28th 2021

Experts in the management of thyroid cancer discuss radioactive iodine therapy and the clinical implications of mutational status in RAI- refractory DTC.

EP. 6: RR-DTC: Molecular Testing Considerations

September 28th 2021

Marcia Brose, MD and Lori Wirth, MD, discuss molecular testing considerations in patients with radioiodine-refractory DTC.

EP. 7: RR-DTC Systemic Therapy Considerations

September 28th 2021

Dr Andrew Gianoukakis, explores considerations surrounding systemic therapy in patients with RAI-refractory differentiated thyroid cancer.

EP. 8: Thyroid Cancer Treatment Guidelines

September 28th 2021

Andrew Gianoukakis, MD, reviews the NCCN guidelines for the treatment of patients with thyroid cancer.

EP. 9: DTC Key Efficacy and Safety Data

September 28th 2021

Dr Andrew Gianoukakis reviews the study design and key efficacy data of the phase 3 DECISION and SELECT trials.

EP. 10: SELECT Trial: Post-Hoc Analysis

September 30th 2021

Andrew Gianoukakis, MD, and Lori Wirth, MD, examine post-hoc analysis data from the phase 3 SELECT trial.